Scientific American Content: Global

Migraine Drug Ubrogepant Tackles Debilitating Early Symptoms

Results from a phase 3 clinical trial suggest that taking ubrogepant at the first sign of an oncoming migraine can prevent preheadache fatigue and light sensitivity

May 14, 2025 - 15:12
 0
Migraine Drug Ubrogepant Tackles Debilitating Early Symptoms

Results from a phase 3 clinical trial suggest that taking ubrogepant at the first sign of an oncoming migraine can prevent preheadache fatigue and light sensitivity

Read More

Tags:

Previous Article

Benro Rhino Carbon Fiber Series Two tripod review

Next Article

Using Real-World Data to Identify Barriers to Treatment Adoption

Related Posts

If a Chatbot Tells You It Is Conscious, Should You Believe It?

If a Chatbot Tells You It Is Conscious, Should You Beli...

May 12, 2025  0

Trump’s Energy Secretary Baselessly Blames Spain’s Power Outage on Renewables

Trump’s Energy Secretary Baselessly Blames Spain’s Powe...

May 12, 2025  0

Solar Geoengineering Is Possible with Existing Aircraft, Study Finds

Solar Geoengineering Is Possible with Existing Aircraft...

May 12, 2025  0